CoChat
Sign Up
Cited by 79Hepatocellular Carcinoma Treatment and PrognosisHepatitis C virus researchLiver physiology and pathology

Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis

Nkontchou, Gisèle, Aout, Mounir, Mahmoudi, Amel, Roulot, Dominique, Bourcier, Valérie, Grando-Lemaire, Véronique, Ganne-Carrie, Nathalie, Trinchet, Jean-Claude +2 more·2012·Cancer Prevention Research
DOI 10.1158/1940-6207.capr-11-0450

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Propranolol bears antioxidant, anti-inflammatory, and antiangiogenic properties and antitumoral effects and therefore is potentially active in the prevention of hepatocellular carcinoma (HCC). We retrospectively assessed the impact of propranolol treatment on HCC occurrence in a cohort of 291 patients with compensated viral C (HCV) cirrhosis, prospectively followed and screened for HCC detection. Of the 291 patients included in the cohort, 93 patients [50 males: mean age, 59.5 ± 12 years; body mass index (BMI), 25.7 ± 4.4 kg/m2; and platelet count, 111 ± 53 Giga/L] developed esophageal varices (OV) or had OV at inclusion and 198 patients (111 males: mean age, 55.8 ± 13 years; BMI, 25.7 ± 5 kg/m2; platelet count, 137 ± 59 Giga/L) did not. Among patients with OV, 50 received treatment by propranolol. During a median follow-up of 54 months interquartile range (32–82), 61 patients developed an HCC. The 3- and 5-year HCC incidence was 4% and 4%, and 10% and 20% for patients treated and not treated by propranolol, respectively (Gray test, P = 0.03). In multivariate analysis, propranolol treatment was associated with a decrease risk of HCC occurrence [HR, 0.25; 95% confidence interval (CI), 0.09–0.65; P = 0.004], and was the only independent predictive factor of HCC occurrence in patients with OV (HR, 0.16; CI, 0.06–0.45; P = 0.0005). The benefit of propranolol was further supported by propensity scores analyses. Conclusion: This retrospective long-term observational study suggests that propranolol treatment may decrease HCC occurrence in patients with HCV cirrhosis. These findings need to be verified by prospective clinical trial. Cancer Prev Res; 5(8); 1007–14. ©2012 AACR.

Integrity signals

Registry

Crossref · 10.1158/1940-6207.capr-11-0450

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A retrospective long-term observational study suggests that propranolol treatment may decrease HCC occurrence in patients with HCV cirrhosis.

    “Interestingly, a retrospective long-term observational study suggests that propranolol treatment might decrease HCC occurrence in patients with HCV cirrhosis158, suggesting a potential role for HCC prevention.”

    From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [158]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Nkontchou, G., Aout, M., Mahmoudi, A., Roulot, D., Bourcier, V., Grando-Lemaire, V., Ganne-Carrie, N., Trinchet, J.-C., Vicaut, E., & Beaugrand, M.
Affiliations
  • Université Sorbonne Paris Nord (FR)
  • Authors' Affiliations: 1Liver Unit, Hôpital Jean Verdier, Bondy; and 2Unit of Clinical Research Hôpital Lariboisiere, Assistance Publique-Hôpitaux de Paris, Université Paris 13, Paris, France
ORCID
Venue
Cancer Prevention Research
Publisher
American Association for Cancer Research (AACR)
Published
2012-08-01
Volume
5
Issue
8
Pages
1007-1014
ISSN
  • 1940-6207 (ISSN-L)
  • 1940-6215
DOI
10.1158/1940-6207.capr-11-0450
OpenAlex
W2060224273
Cited by
79
References
44
Citations by year
2026: 3 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 8 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 14 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 3
FWCI
3.23
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Prevention Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
propranolol, hepatocellular carcinoma, hepatitis C cirrhosis, hepatocellular carcinoma incidence, esophageal varices, HCC prevention, antiangiogenic activity, HCV-associated liver disease
MeSH terms
Aged, Female, Follow-Up Studies, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Propranolol, Prospective Studies, Retrospective Studies, Vasodilator Agents, Incidence, Survival Rate, Hepacivirus, Hepatitis C, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review